HDBuzz covers newly published research on branaplam
Posted on March 17, 2022
A study recently published in Nature detailed scientists’ understanding of how branaplam, a drug originally developed for treatment of spinal muscular atrophy…
Read MoreThe Editors of HDBuzz cover the CHDI Therapeutics Conference
Posted on March 10, 2022
For the first time in two years, scientists, clinicians, and industry partners convened in Palm Springs, CA for CHDI foundation’s 17th Annual HD Therapeutics Conference….
Read MoreHDBuzz Covers the CHDI Conference
Posted on March 3, 2022
CHDI is a privately funded HD research foundation whose mission is to further development of HD therapies. This week, they’re hosting…
Read MoreRaise Awareness of Rare Disease Day with HDSA February 28th
Posted on February 24, 2022
When you have a rare disease, you face two battles – one being the illness itself, and the other, living…
Read MoreQuick Question: Genetic Testing and Rare Disease
Posted on February 17, 2022
Check out HDSA’s new short video series, “Quick Question,” in which HDSA’s Jennifer Simpson, LCSW (Assistant Director of Youth &…
Read MoreA new mouse model for HD: The scoop from HDBuzz
Posted on February 10, 2022
Researchers at UCLA have developed a new mouse model for HD that more closely resembles human HD than ever before….
Read MoreSplicing Modulators for HD: HDBuzz Covers PTC Therapeutics’ HTT-lowering approach
Posted on February 3, 2022
Huntingtin lowering (HTT-lowering) has been touted as a promising avenue for treatment of HD because it targets the cause of…
Read MoreUpdate from Novartis on Planned Trial of Branaplam for Huntington’s Disease
Posted on January 27, 2022
Novartis is developing an experimental HD therapy called branaplam which has the potential to lower huntingtin when taken by mouth. Branaplam…
Read MoreRoche to continue development of tominersen: Community Presentation TODAY
Posted on January 20, 2022
In a community letter released January 18th, Roche announced plans to continue developing the huntingtin-lowering drug tominersen. After analyzing data collected in the Phase III GENERATION HD-1 trial that halted dosing in…
Read MoreResearch Webinar: Roche Joins HDSA to Discuss Latest Data from GENERATION HD-1
Posted on January 13, 2022
One week from today, HDSA will be joined by members of the Roche team at 3:00 PM EST on January 20th for…
Read MoreUpcoming Webinar: New Key Findings from the GENERATION HD-1 Study
Posted on January 6, 2022
Join HDSA at 3:00 PM EST on January 20th for an update from Roche on new findings from the data collected in the GENERATION HD-1 study. This…
Read More